Progress in the treatment of multiple myeloma

doi:10.12092/j.issn.1009-2501.2020.01.016

Abstract

Abstract: Multiple myeloma is a malignant tumor that occurs in plasma cells. Clonal plasma cells in bone marrow proliferate abnormally and secrete monoclonal immunoglobulin or its fragment (M protein), resulting in damage to related organs or tissues. At present, with the development of new drugs, the development of cellular immunotherapy and the improvement of hematopoietic stem cell transplantation technology, the depth of remission and survival of multiple myeloma are significantly prolonged. This article reviews the latest advances in the treatment of multiple myeloma in recent years.

Key words: multiple myeloma, proteasome inhibitor, immunomodulator, immunotherapy, hematopoietic stem cell transplantation

CLC Number:

R551.3

CHANG Xiangxiang, WEI Zhongling, ZHENG Xingyuan, LI Huimin, HUANG Laiquan. Progress in the treatment of multiple myeloma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 107-116.

References

［1］Torimoto Y, Shindo M, Ikuta K, et al. Current therapeutic strategies for multiple myeloma ［J］. Int J Clin Oncol, 2015, 20(3): 423-430.
［2］黄月华, 潘崚. 硼替佐米的作用机制、临床应用及其疗效研究进展［J］. 实用诊断与治疗杂志, 2008, 22(4): 280-282.
［3］Chakraborty R, Muchtar E, Kumar S, et al. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents［J］. Bone Marrow Transplant, 2017, 52(1): 34-40.
［4］Lakshman A, Singh PP, Rajkumar SV, et al. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma［J］. Am J Hematol, 2018, 93(2): 179-186.
［5］Gao M, Yang G, Han Y, et al. Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trials［J］. Int J Clin Exp Med, 2015, 8(8): 12202-12210.
［6］Spencer A, Lentzsch S, Weisel K, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR［J］. Haematologica, 2018, 103(12): 2079-2087.
［7］Zanwar S, Abeykoon JP, Kapoor P. Ixazomib: a novel drug for multiple myeloma［J］. Expert Rev Hematol, 2018, 11(10): 761-771.
［8］Gupta N, Hanley MJ, Xia C, et al. Clinical pharmacology of ixazomib: The first oral proteasome inhibitor ［J］. Clin Pharmacokinet, 2019, 58(4): 431-449.
［9］Hou J, Jin J, Xu Y, et al. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study［J］. J Hematol Oncol, 2017, 10(1): 137.
［10］Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study［J］. Lancet Oncol, 2014, 15(13): 1503-1512.
［11］Gupta N, Diderichsen PM, Hanley MJ, et al. Population pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor, including data from the phase III TOURMALINE-MM1 study to inform labelling ［J］. Clin Pharmacokinet, 2017, 56(11): 1355-1368.
［12］Touzeau C, Moreau P. Ixazomib in the management of relapsed multiple myeloma［J］. Future Oncol, 2018, 14(20): 2013-2020.
［13］Spencer A, Harrison S, Zonder J, et al. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results［J］. Br J Haematol, 2018, 180(1): 41-51.
［14］Di K, Lloyd GK, Abraham V, et al. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier［J］. Neuro Oncol, 2016, 18(6): 840-848.
［15］Badros A, Singh Z, Dhakal B, et al. Marizomib for central nervous system-multiple myeloma［J］. Br J Haematol, 2017, 177(2): 221-225.
［16］Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma［J］. Leuk Lymphoma, 2013, 54(4): 683-687.
［17］Soyer N, Patir P, Uysal A, et al. Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: a real-life experience［J］. Turk J Med Sci, 2018, 48(4): 777-785.
［18］Fuchida SI, Sunami K, Matsumoto M, et al. A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma［J］. Int J Hematol, 2019, 109(1): 131. doi: 10.1007/s12185-018- 2557-5.
［19］Wang X, Walter M, Urak R, et al. Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma［J］. Clin Cancer Res, 2018, 24(1): 106-119.
［20］Kneppers E, van der Holt B, Kersten MJ, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial［J］. Blood, 2011, 118(9): 2413-2419.
［21］Mikhael J,Manola J,Dueck AC,et al.Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function:PrE1003, a PrECOG study［J］.Blood Cancer J,2018,8(9): 86.
［22］Endo S, Amano M, Nishimura N, et al. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells［J］. Biochem Biophys Res Commun, 2016, 469(2): 236-242.
［23］Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial［J］. Lancet Oncol, 2013, 14(11): 1055-1066.
［24］Charlinski G, Grzasko N, Jurczyszyn A, et al. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience［J］. Eur J Haematol, 2018, 101(3): 354-361.
［25］Leleu X, Karlin L, Macro M, et al. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results［J］. Blood, 2015, 125(9): 1411-1417.
［26］Guedan S, Calderon H, Posey A J, et al. Engineering and design of chimeric antigen receptors［J］. Mol Ther Methods Clin Dev, 2019,12: 145-156.
［27］Garfall AL, Stadtmauer EA, Hwang W, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.［J］. JCI Insight, 2018, 3(8): e120505.
［28］Guo B, Chen M, Han Q, et al. CD138- directed adoptive immunotherapy of chimeric antigen receptor（CAR）-modified T cells for multiple myeloma［J］. J Cell Immunother, 2015, 2(1): 28-35.
［29］Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma［J］. Blood, 2016, 128(13): 1688-1700.
［30］Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma ［J］. J Clin Oncol, 2018, 36(22): 2267-2280.
［31］Chen KH, Wada M, Pinz KG, et al. A compound chimeric antigen receptor strategy for targeting multiple myeloma［J］. Leukemia, 2018, 32(2): 402-412.
［32］Lee L, Draper B, Chaplin N, et al. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma［J］. Blood, 2018, 131(7): 746-758.
［33］Maus MV, June CH. Zoom Zoom: racing CARs for multiple myeloma［J］. Clin Cancer Res, 2013, 19(8): 1917-1919.
［34］Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma［J］. N Engl J Med, 2016, 375(8): 754-766.
［35］Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma［J］. N Engl J Med, 2016, 375(14): 1319-1331.
［36］Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma［J］. N Engl J Med, 2018, 378(6): 518-528.
［37］Dimopoulos MA, Sonneveld P, Leung N, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment［J］. J Clin Oncol, 2016, 34(13): 1544-1557.
［38］Rocchi S, Tacchetti P, Pantani L, et al. Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma［J］. Haematologica, 2018, 103(6): e277-e278.
［39］Liu YC, Szmania S, van Rhee F. Profile of elotuzumab and its potential in the treatment of multiple myeloma［J］. Blood Lymphat Cancer, 2014, 2014(4): 15-27.
［40］Lonial S, Kaufman J, Laubach J, et al. Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma［J］. Expert Opin Biol Ther, 2013, 13(12): 1731-1740.
［41］Lamb YN. Elotuzumab: a review in relapsed and/or refractory multiple myeloma ［J］. Drugs, 2018, 78(14): 1481-1488.
［42］Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma［J］. N Engl J Med, 2015, 373(7): 621-631.
［43］Dimopoulos MA, Lonial S, Betts KA, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial［J］. Cancer, 2018, 124(20): 4032-4043.
［44］Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer［J］. N EngI J Med, 2012, 366(26): 2443-2454.
［45］Jing W, Gershan JA, Weber J, et al. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma［J］. J Immunother Cancer, 2015, 3(1):2.
［46］Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma［J］. Blood, 2017, 130(10): 1189-1197.
［47］Chan WK, Kang S, Youssef Y, et al. A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma［J］. Cancer Immunol Res, 2018, 6(7): 776-787.
［48］Seckinger A, Delgado JA, Moser S, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment ［J］. Cancer Cell, 2017, 31(3): 396-410.
［49］Zou J, Chen D, Zong Y, et al. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma［J］. Cancer Sci, 2015, 106(5): 512-521.
［50］Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial［J］. Lancet Oncol, 2011, 12(13): 1195-1203.
［51］Htut M, D'Souza A, Krishnan A, et al. Autologous/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: comparison of long-term postrelapse survival［J］. Biol Blood Marrow Transplant, 2018, 24(3): 478-485.
［52］张彤彤, 孙爱宁, 陈苏宁, 等. 381例血液病患者造血干细胞移植术后相关感染的临床分析［J］. 中华血液学杂志, 2014, 35(9): 857-859.
［53］Tamaki M, Nakasone H, Gomyo A, et al. Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan［J］. Int J Hematol, 2018, 108(4): 423-431.
［54］Qazilbash HM, Bashir QM. 399 A randomized phase III trial of busulfan + melphalan VS melphalan alone for multiple myeloma［J］. 2017.
［55］Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival ［J］. J Clin Oncol, 2008, 26(35): 5775-5782.
［56］Aggarwal M, Agrawal N, Yadav N, et al. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma［J］. Ann Hematol, 2018, 97(10): 1869-1877.
［57］Stewart AK, Trudel S, Bahlis NJ, et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial［J］. Blood, 2013, 121(9): 1517-1523.
［58］Bergsagel PL, Mateos MV, Gutierrez NC, et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma［J］. Blood, 2013, 121(6): 884-892.

[1]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[2]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[3]	QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
[4]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[5]	ZHU Ruifang, GUO Dongkai, ZHI Hui, JIANG Yiguo, ZHANG Yueling, QIAN Xiaoping, JI Shiliang. Exploring the mechanism of elemene synergistic bortezomib against multiple myeloma by ROS-NF-κB-p38MAPK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1219-1226.
[6]	WANG Tiantian, CAO Junjie, LIU Xuhui, PEI Renzhi, LU Ying. Clinical analysis of the effect of fludarabine combined with post-transplantation cyclophosphamide in haploid hematopoietic stem cell transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 295-301.
[7]	DUAN Yuanyuan, LI Zijian. Ciltacabtagene autoleucel—a novel BCMA-directed CAR T-cell therapy in patients with relapsed or refractory multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1145-1154.
[8]	LI Wei, HU Jiali, WANG Kai, HE Yijing. Research progress and prospect of immunotherapy in the treatment of melanoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1053-1064.
[9]	BAO Jing, CHEN Xiaowen, XIA Liang, ZHAO Yuchen, XIA Ruixiang, XIA Hailong. Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 782-786.
[10]	PENG Min, HUANG Panhao, DENG Yinhua, LIU Wen, LI Wei, YU Zhen, XIA Qing, XIE Yueliang. Analysis of influence factors of voriconazole trough concentration in patients with hematopoietic stem cell transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 640-646.
[11]	MIN Hang, GUO Mengran, YE Yue, XU Xiaoshuang, ZHEN Donghu. Research progress of thyroid dysfunctions during treatment with immune-checkpoint inhibitors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 223-229.
[12]	ZHAO Quanming, YANG Yang. Progress in drug therapy for advanced triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 475-480.
[13]	ZHANG Kaiting, CHEN Naihan. Development of therapeutic biologics in cancer treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 32-43.
[14]	FENG Yuanyuan, DING Kaiyang, WANG Cuicui. Clinical observation of 40 patients with malignant lymphoma treated with high dose chemotherapy combined with autologous hematopoietic stem cell transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1397-1401.
[15]	ZHANG Xiaoying, WANG Kang, WU Sha, GUO Peng. Association analysis of low dose olanzapine in controlling mental symptoms of NMDAR encephalitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1292-1296.